Aurealis Pharma Ltd.
Three-in-one combination therapy in one single product
Aurealis Pharma, a privately-held biopharmaceutical company, has developed a broadly applicable technology platform that enables three-in-one combination therapy in one single product. This effective, safe and economical treatment method can greatly improve the quality of life of people suffering from these major unmet medical needs such as cancer.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
06.11.2024
Biotech companies report progress in clinical trials (startupticker.ch)
10.05.2023
Biotech startups turn gear into Phase 2 clinical trials (startupticker.ch)
04.04.2023
Aurealis Therapeutics banks $10 million in an oversubscribed round (startupticker.ch)
31.01.2022
Aurealis to receive up to $139 million in collaboration agreement (startupticker.ch)
12.02.2020
Aurealis Therapeutics startet 1-2A-Studie (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
Aurealis Pharma Ltd.
Three-in-one combination therapy in one single product
Website:
www.aurealispharma.com/en/
Headquarter:
Jonen
Foundation Date:
September 2015
Technology:
- Biotech
Sectors:
- Biotech
- Cancer